Company: BGLC
Filing Date: 2025-12-03
Form Type: DEF 14A
Source: 0001477932-25-008757
Chunk: 17

Company: BioNexus Gene Lab Corp
Filing Date: 2025-12-03
Form: DEF 14A
Chunk 17
---
 value. A fundamental part of risk oversight is not only understanding the risks a Company faces and what steps management is taking to manage those risks, but also understanding what level of risk is appropriate for the Company. As a critical part of this risk management oversight role, our Board encourages full and open communication between management and the Board. Our Board regularly reviews material strategic, operational, financial, compensation and compliance risks with management. In addition our management team regularly reports to the full Board regarding their areas of responsibility and a component of these reports is risk within the area of responsibility and the steps management has taken to monitor and control such exposures. Additional review or reporting on risk is conducted as needed or as requested by our Board.

Insider Trading Arrangements and Policies

The Company has adopted a Code of Business Conduct and Ethics that applies to all directors, officers, and employees. This Code includes policies and procedures governing the purchase, sale, and other dispositions of our securities that are reasonably designed to promote compliance with insider trading laws, rules, and regulations. A copy of our Code of Business Conduct and Ethics, which contains these insider trading provisions, has been filed as an exhibit to our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Attendance

There were 4 meetings, exclusive of action by unanimous written consent, of the Board held during fiscal year 2024. During the fiscal year, all Directors attended at least 75% of the aggregate number of meetings of the Board, except Ms. Jook Yuen Low who attended 1 meeting after her appointment on November 5, 2024. The Company held an annual meeting of stockholders in fiscal year 2024 and Mr. Su-Leng Tan Lee, Mr. Muhammad Azrul bin Abdul Hamid, and Mr. Chee Keong Yap were duly elected at that meeting. We encourage our directors to attend the annual meeting of stockholders.

There were 2 meetings each, exclusive of action by unanimous written consent, of the Nominating and Corporate Governance Committee and Compensation Committee held during fiscal year 2024. There were 4 meetings held by the Audit Committee in conjunction with the Quarterly reporting schedule, and an additional 2 Executive Sessions of only the Independent Members of the Board of Directors.

Board Diversity Matrix

The following chart summarizes certain self-identified personal characteristics of our directors, in accordance with Nasdaq Listing Rule 5605(f).

| 13 |

Each term used in the table has the meaning given to it in